Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867147 · ClinicalTrials.gov registry record · Phase 1
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05867147 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 56 participants.
The verdict
NCT05867147, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
Interventions
- DRUG Moxifloxacin
- DRUG Moxifloxacin Placebo
- DRUG Vanzacaftor
- DRUG Vanzacaftor Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05867147
The ClinicalTrials.gov registry entry for NCT05867147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT05867147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05867147 about?
NCT05867147 is a clinical study titled "An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants". The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
What is the current status of trial NCT05867147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-04-26. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05867147?
The interventions under investigation include: Moxifloxacin (DRUG), Moxifloxacin Placebo (DRUG), Vanzacaftor (DRUG), Vanzacaftor Placebo (DRUG).
Who is sponsoring clinical trial NCT05867147?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.